Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Medifocus Inc. Announces Launch of New Website
Updated Corporate Presentation Available; Highlights Initial Revenue From Prolieve(R) Thermodilatation System and Clinical Strategy for Completion of Phase III Trial for Commercialization of APA 1000(R) System

TORONTO and BALTIMORE, MD -- (Marketwire) -- 02/06/13 -- Medifocus, Inc. (OTCQX: MDFZF), (TSX VENTURE: MFS) (Medifocus or the Company), a commercial stage, revenue producing biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce the launch of its new website, available at www.medifocusinc.com.

The new website highlights the Company's progress as it begins to generate revenue from its recently acquired Prolieve® Thermodilatation System for the treatment of BPH (Benign Prostatic Hyperplasia). BPH is a medical condition resulting from an enlarged prostate which is common among males over 50 years of age. The new website also shares the Company's clinical strategy for the completion of its existing Phase III trial for the commercialization of its APA 1000®, System, which focuses on the treatment of breast cancer. An updated corporate presentation has been placed within the investor section and can be found at http://medifocusinc.com/?page_id=338.

Dr. Augustine Y. Cheung, President and CEO of Medifocus, commented, "In the past two quarters we have made tremendous revenue growth with the rollout of our Prolieve® Thermodilatation System, which focuses on the treatment of BPH. This 45-minute office procedure has been approved as an alternative to drug therapy. We look forward to sharing this progress through our newly designed website."

Cheung continued, "We believe that, in addition to achieving a solid update on our therapeutic programs, visitors will now be able to achieve a clear understanding of how our substantial patent portfolio positions us favorably within our sector of the cancer therapeutic market and affords us tremendous growth opportunity as we further develop our heat treatment technologies."

About Medifocus, Inc.

Medifocus develops and commercializes minimally invasive, unique focused heat treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, or Benign Prostatic Hyperplasia ("BPH").

The Company owns two technology platforms with comprehensive US and international patent protection: The "Endo-thermotherapy Platform" and the "Adaptive Phased Array Microwave Focusing Platform". Based on these platform technologies, the Company has developed two advanced therapeutic products: the Prolieve® system for the treatment of BPH, and the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer.

The U.S. FDA-approved Prolieve® System (www.prolieve.com) is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The heating plus dilatation treatment offered by the Prolieve® System is the only minimally invasive treatment which offers both immediate and long term relief of symptoms due to enlarged prostate (BPH) in men. The clinical indication received for Prolieve® from the FDA is an "alternative to drug therapy." With this indication, the Prolieve® System is a revenue generating device based product which can have the potential of catering to the $8 billion non-surgical prescription drug therapy market for treatment of BPH.

The APA-1000 uses precisely focused and controlled microwave energy to shrink breast cancer tumors without side effects on the surrounding tissues to produce better treatment outcomes. The Company has received regulatory approvals to complete, and has now begun the APA 1000's pivotal Phase-III clinical trials. Successful completion of the phase III trial will lead to commercial approval (PMA) of the product.

The Company is currently focusing on increasing revenue from the Prolieve® system for the treatment of BPH and completing the APA 1000 breast cancer system's Phase III study. For more information, visit www.medifocusinc.com.

Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus's future growth resulting from the election of Mr. Yam and the expectation that sales from Prolieve® will accelerate. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Company Contact:
Dr. Augustine Y. Cheung
President and CEO
Medifocus, Inc.
Tel: 443-832-4854
acheung@medifocusinc.com

Mr. Douglas Liu
Director of Business Development
Medifocus, Inc.
Tel: 410-290-5734
dliu@medifocusinc.com

Investor Relations Contact:
Robert Giordano
Consulting for Strategic Growth 1
T: 917-327-3938
rgiordanonyc@gmail.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
For retailers everywhere, it’s a challenging new day. Security threats are a constant – both inside their four walls and out. The big security breaches we hear about on the news; the smaller ones sometimes not. But their impact remains costly to us all. The need for mobility, rapidly e...
I write and study often on the subject of digital transformation - the digital transformation of industries, markets, products, business models, etc. In brief, digital transformation is about the impact that collected and analyzed data can have when used to enhance business processes ...
I had the privilege of attending a mobile security event this week and speaking with many experts on the matter. I am not a mobile security expert, so my role was to speak on mobile strategies and trends and to learn as much as I could. What did I learn? I learned the difference b...
General Electric (GE) has been a household name for more than a century, thanks in large part to its role in making households easier to run. Starting with the light bulb invented by its founder, Thomas Edison, GE has been selling devices (“things”) to consumers throughout its 122-year...
It's time to condense all I've seen, heard, and learned about the IoT into a fun, easy-to-remember guide. Without further ado, here are Five (5) Things About the Internet of Things: 1. It's the end-state of Moore's Law. It's easy enough to debunk the IoT as “nothing new.” After all,...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE